Diagnostic test for Mammalian TB

Interested organisations are invited to submit the requested information (outlined below), via email, to Melanie Swain (melanie.swain@defra.gov.uk), by 30th January 2026: - Details of any suitable product(s) currently under development. - The type(s) of test being developed or already available. - The underlying technology used in the test(s). - Practical considerations for field deployment, including portability, power requirements, and methods for obtaining and recording test results. - Knowledge or training requirements for operators/end-users. - Ability and willingness to incorporate diagnostic targets into the test (e.g., antigens) as specified by APHA. - Whether antigen production capability exists alongside test production. - The nature and minimum volume of the diagnostic sample required for testing. - Time required to obtain a test result. - Operational temperature range. - Storage conditions and shelf-life. - Species for which the test is developed or intended. - Expected or demonstrated performance metrics, including sensitivity, specificity, and predictive values (positive and negative). - Any data on cross-reactivity with environmental mycobacteria, BCG vaccine (DIVA capability), or other common pathogens. - Information on validation, reproducibility, and repeatability. - Estimated date of product availability. - Evidence of use in other regions or countries. - Details of any licences or certifications held or required. - Indicative wholesale and retail pricing information, if available. This Notice is for information-gathering purposes only. It does not constitute a call for competition and does not guarantee any future procurement activity. Should a tender opportunity arise, suppliers will need to formally express their interest following the publication of a Contract Notice on Find a Tender. APHA reserves the right to follow up with suppliers on a 1:1 basis to further understand their capabilities regarding this requirement.